RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
Redhill Biopharma Ltd. - American Depositary Shares (RDHL)
US:NASDAQ Investor Relations:
ir.redhillbio.com/investor-relations
Company Research
Source: PR Newswire
New U.S. patent issued covering the identification of a novel biomarker of coronavirus pneumonia (=60% fraction of inspired oxygen (FiO2)) prognostic for potential opaganib efficacy in treating COVID-19, valid through 204Published post-hoc data from opaganib's Phase2/3 study showed that patients with =60% FiO2 levels had better outcomes after 14 days' opaganib treatment (n=117) compared to placebo (n=134), including: increased number of patients no longer requiring supplemental oxygen by day 14 of opaganib treatment (76.9% vs. 63.4%; p-value =0.033), a 62.6% reduction in intubation/mechanical ventilation (6.84% vs. 17.91%; p-value=0.012) and a clinically meaningful 62% reduction in mortality (5.98% vs. 16.7%; p-value=0.019) by day 42[1]With multiple U.S. government collaborations for medical countermeasure and pandemic preparedness, opaganib is a novel, host-directed, potentially broad acting, orally administered small molecule drug with demonstrated safety & efficacy profiles, being
Show less
Read more
Impact Snapshot
Event Time:
RDHL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDHL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDHL alerts
High impacting Redhill Biopharma Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
RDHL
News
- RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRNDPR Newswire
- RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation InjuryPR Newswire
- RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola TreatmentPR Newswire
- RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million CaliforniansPR Newswire
- RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology GuidelinesPR Newswire